BNTC
Benitec Biopharma Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-38/100
Last price
9.00
▼ 0.23 (2.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
9.23
Day high
9.57
Day low
8.62
Volume
217.15K
Market cap
$313.94M
P/E (TTM)
—
52W range
8.52 – 16.76
Trailing performance
Returnvs SPY
1W
-7.69%
-9.6%
1M
-29.02%
-30.2%
3M
-33.23%
-37.8%
6M
-17.51%
-35.7%
YTD
-33.18%
-47.4%
1Y
-34.97%
-51.4%
3Y
+197.82%
+115.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BNTC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
875.56K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 29, 26 | BUCHI J. KEVIN Director |
STOCK | 51.81K | $0 | Direct |
| Dec 29, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 144.22K | $1.90M | Indirect |
| Dec 22, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 46.14K | $538.97K | Indirect |
| Nov 7, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.48M | $20.00M | Indirect |
| Mar 31, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 16.50K | $211.74K | Indirect |
| Mar 26, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 900.00K | $11.70M | Indirect |
| Mar 12, 25 | BUCHI J. KEVIN Director |
STOCK | 103.63K | $0 | Direct |
| Feb 27, 25 | BUCHI J. KEVIN Director |
CONVERSION | 51.81K | $200.00K | Direct |
| Dec 24, 24 | SUVRETTA CAPITAL MANAGEMENT, LLC Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 47.52K | $527.17K | Indirect |
| Dec 3, 24 | SUVRETTA CAPITAL MANAGEMENT, LLC Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 42.00K | $403.20K | Indirect |
| Nov 20, 24 | SUVRETTA CAPITAL MANAGEMENT, LLC Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 41.44K | $416.62K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUCHI J. KEVIN |
Director | 52.10K | Stock Gift |
SUVRETTA CAPITAL MANAGEMENT, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$313.94M
Enterprise value$134.73M
Revenue (TTM)—
Gross profit—
EBITDA$-51.13M
Net income$-45.55M
EPS (TTM)$-0.98
Free cash flow$-2.75M
Total cash$179.97M
Total debt$762.00K
Book value / share$5.14
Shares outstanding34.88M
Float18.45M
Short % of float10.96%
Dividend yield0.00%
Beta (5Y)0.25
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.96
PEG ratio—
Price / sales—
Price / book1.75
EV / revenue—
EV / EBITDA-2.64
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-33.21%
Return on assets-22.67%
Debt / equity0.43
Current ratio34.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $75.00K | — | — |
| Operating revenue | $0 | $0 | $0 | $75.00K | — | — |
| Cost of revenue | — | — | — | $0 | $9.00K | — |
| Gross profit | — | — | — | $75.00K | $64.00K | — |
| Research & development | $23.39M | $18.33M | $15.61M | $12.77M | — | +27.6% |
| Selling, general & admin | $27.80M | $23.43M | $6.99M | $6.38M | — | +18.7% |
| Total operating expense | $51.19M | $41.77M | $22.49M | $19.16M | — | +22.6% |
| Operating income | -$51.19M | -$41.77M | -$22.49M | -$19.08M | — | -22.6% |
| Net interest income | $5.57M | $3.29M | $904.00K | -$33.00K | — | +69.5% |
| Pre-tax income | -$45.55M | -$37.92M | -$21.75M | -$19.56M | — | -20.1% |
| Net income | -$45.55M | -$37.92M | -$21.75M | -$19.56M | — | -20.1% |
| Net income to common | -$45.55M | -$37.92M | -$22.37M | -$19.56M | — | -20.1% |
| Basic EPS | -0.98 | -1.05 | -1.22 | -14.12 | — | +6.7% |
| Diluted EPS | -0.98 | -1.05 | -1.22 | -14.12 | — | +6.7% |
| EBIT | -$51.19M | -$41.77M | -$22.49M | -$19.08M | — | -22.6% |
| EBITDA | -$50.71M | -$41.37M | -$22.15M | -$18.70M | — | -22.6% |
| Basic shares | 46.56M | 36.21M | 18.36M | 1.39M | — | +28.6% |
| Diluted shares | 46.56M | 36.21M | 18.36M | 1.39M | — | +28.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $179.97M | $97.74M | $50.87M | $2.48M | +84.1% |
| Cash & short-term investments | $179.97M | $97.74M | $50.87M | $2.48M | +84.1% |
| Accounts receivable | $4.00K | $33.00K | $229.00K | $55.00K | -87.9% |
| Total current assets | $181.69M | $98.52M | $51.67M | $3.73M | +84.4% |
| Property, plant & equipment | $871.00K | $991.00K | $449.00K | $613.00K | -12.1% |
| Total assets | $182.62M | $99.59M | $52.21M | $4.46M | +83.4% |
| Total current liabilities | $5.34M | $1.80M | $4.92M | $3.98M | +196.6% |
| Total debt | $762.00K | $849.00K | $284.00K | $559.00K | -10.2% |
| Total liabilities | $5.61M | $2.30M | $4.96M | $4.26M | +144.2% |
| Retained earnings | -$273.72M | -$228.18M | -$190.26M | -$167.89M | -20.0% |
| Shareholder equity | $177.01M | $97.30M | $47.25M | $202.00K | +81.9% |
| Working capital | $176.34M | $96.72M | $46.75M | -$249.00K | +82.3% |
| Net tangible assets | $177.01M | $97.30M | $47.25M | $202.00K | +81.9% |
| Shares issued | 34.42M | 26.25M | 10.09M | 1.65M | +31.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$45.55M | -$37.92M | -$21.75M | -$19.56M | -20.1% |
| Depreciation & amortisation | $481.00K | $396.00K | $343.00K | $381.00K | +21.5% |
| Stock-based compensation | $26.41M | $17.43M | $830.00K | $452.00K | +51.6% |
| Change in working capital | $2.14M | -$2.73M | $1.17M | $714.00K | +178.3% |
| Operating cash flow | -$16.52M | -$23.59M | -$19.40M | -$18.01M | +30.0% |
| Capital expenditure | -$105.00K | -$18.00K | -$179.00K | -$1.00K | -483.3% |
| Investing cash flow | -$105.00K | -$18.00K | -$179.00K | -$1.00K | -483.3% |
| Financing cash flow | $98.98M | $70.48M | $68.03M | $16.02M | +40.4% |
| Free cash flow | -$16.62M | -$23.61M | -$19.58M | -$18.01M | +29.6% |
| End cash position | $180.09M | $97.86M | $50.93M | $2.49M | +84.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | — | $0 | — |
| Research & development | $7.89M | $6.30M | $5.83M | $3.37M | $3.69M | — | +25.2% |
| Selling, general & admin | $6.54M | $7.28M | $7.54M | $6.43M | $13.48M | — | -10.2% |
| Total operating expense | $14.43M | $13.58M | $13.38M | $9.80M | $17.18M | — | +6.2% |
| Operating income | -$14.43M | -$13.58M | -$13.38M | -$9.80M | -$17.18M | — | -6.2% |
| Net interest income | $1.57M | $1.59M | $1.39M | $1.01M | $1.04M | — | -1.3% |
| Pre-tax income | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$16.15M | — | -7.3% |
| Net income | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$16.15M | — | -7.3% |
| Net income to common | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$16.15M | — | -7.3% |
| Basic EPS | — | -0.24 | -0.26 | -0.22 | — | -0.38 | — |
| Diluted EPS | — | -0.24 | -0.26 | -0.22 | — | -0.38 | — |
| EBIT | -$14.43M | -$13.58M | -$13.38M | -$9.80M | -$17.18M | — | -6.2% |
| EBITDA | -$14.31M | -$13.46M | -$13.26M | -$9.69M | -$17.06M | — | -6.3% |
| Basic shares | — | 49.39M | 45.97M | 41.52M | — | 38.60M | — |
| Diluted shares | — | 49.39M | 45.97M | 41.52M | — | 38.60M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $179.97M | $184.76M | $188.79M | $94.48M | $97.74M | -2.6% |
| Cash & short-term investments | $179.97M | $184.76M | $188.79M | $94.48M | $97.74M | -2.6% |
| Accounts receivable | $4.00K | $3.00K | $130.00K | $7.00K | $33.00K | +33.3% |
| Total current assets | $181.69M | $186.02M | $189.59M | $95.08M | $98.52M | -2.3% |
| Property, plant & equipment | $871.00K | $916.00K | $1.02M | $873.00K | $991.00K | -4.9% |
| Total assets | $182.62M | $187.00M | $190.68M | $96.03M | $99.59M | -2.3% |
| Total current liabilities | $5.34M | $3.27M | $2.80M | $2.02M | $1.80M | +63.2% |
| Total debt | $762.00K | $876.00K | $987.00K | $817.00K | $849.00K | -13.0% |
| Total liabilities | $5.61M | $3.67M | $3.32M | $2.43M | $2.30M | +52.9% |
| Retained earnings | -$273.72M | -$260.91M | -$248.98M | -$237.14M | -$228.18M | -4.9% |
| Shareholder equity | $177.01M | $183.33M | $187.36M | $93.60M | $97.30M | -3.4% |
| Working capital | $176.34M | $182.74M | $186.79M | $93.05M | $96.72M | -3.5% |
| Net tangible assets | $177.01M | $183.33M | $187.36M | $93.60M | $97.30M | -3.4% |
| Shares issued | 34.42M | 34.35M | 34.25M | 26.25M | 26.25M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$16.15M | — | -7.3% |
| Depreciation & amortisation | $124.00K | $119.00K | $120.00K | $118.00K | $118.00K | — | +4.2% |
| Stock-based compensation | $6.26M | $7.59M | $7.38M | $5.18M | $13.45M | — | -17.6% |
| Change in working capital | $1.49M | -$228.00K | $562.00K | $316.00K | -$5.63M | — | +752.2% |
| Operating cash flow | -$4.94M | -$4.45M | -$3.78M | -$3.35M | -$8.21M | — | -10.9% |
| Capital expenditure | -$79.00K | -$15.00K | — | — | — | -$6.00K | -426.7% |
| Investing cash flow | -$79.00K | -$15.00K | -$11.00K | $0 | $0 | — | -426.7% |
| Financing cash flow | $241.00K | $506.00K | $98.23M | $0 | $2.54M | — | -52.4% |
| Free cash flow | -$5.02M | -$4.47M | -$3.79M | -$3.35M | -$8.21M | — | -12.3% |
| End cash position | $180.09M | $184.88M | $188.90M | $94.59M | $97.86M | — | -2.6% |
Options analytics
Put / call volume
0.25
Call-heavy session
Put / call open interest
1.20
Positioning, not flow
Max pain
10.00
+11.1% from spot
ATM implied vol
782.8%
Nearest strike to spot
Skew (10% OTM)
-475.0%
Calls bid over puts
Call volume
4
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
10.00
4 contracts
Heaviest put OI
17.50
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.27 | -0.26 | +1.9% |
| Mar 2026 | -0.28 | -0.24 | +12.7% |
| Dec 2025 | -0.23 | -0.26 | -15.0% |
| Sep 2025 | -0.36 | -0.22 | +38.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.28 | 4 | $0 | 0.0% |
| Next quarter | -0.30 | 4 | $0 | 0.0% |
| Current year | -1.20 | 5 | $0 | 0.0% |
| Next year | -1.33 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$24.33
High target$32.00
Low target$17.00
Implied upside170.37%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders2.51%
Held by institutions96.07%
Institutions holding123
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.56
-5.88% from price
SMA 20
10.54
-14.64% from price
SMA 50
11.84
-23.98% from price
SMA 100
11.88
-24.23% from price
SMA 200
11.88
-24.24% from price
EMA 12
9.83
-8.45% from price
EMA 26
10.66
-15.56% from price
EMA 50
11.32
-20.47% from price
RSI (14)
29.8
Oversold
MACD (12,26,9)
-0.83
Hist -0.11
ATR (14)
0.84
9.30% of price
Realised vol 30D
54.4%
Annualised
Bollinger upper
12.74
20, 2σ
Bollinger lower
8.35
20, 2σ
50 / 200 cross
Death
11.84 vs 11.88
Trend bias
Below 200
-24.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.39
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
54.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-45.6%
Peak to trough
Max drawdown 5Y
-97.0%
Peak to trough
ATR 14
0.84
9.30% of price
Beta (reported)
0.25
5Y monthly, from filing
Short interest
Shares short
2.19M
Prior 2.11M
Change vs prior
+3.7%
Shorts adding
% of float
10.96%
Elevated
% of shares out
6.27%
Against total outstanding
Days to cover
16.2
Crowded exit
Float
18.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 28, 26 | Wedbush | INITIATED | — | Outperform |
| May 12, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| Mar 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 24, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 4, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 4, 25 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Sep 24, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Sep 16, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Apr 10, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateNov 18, 2019
Last split1:17
Split dateJul 26, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-09-24
Offering Registrations
S-3 · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-14
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-20
Periodic Financial Reports
10-Q · 2026-02-12
Headlines
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
GlobeNewswire · 2d ago
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Zacks · 12d ago
Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating
MT Newswires · 22d ago
Benitec Biopharma Files $200 Million Shelf Registration
MT Newswires · 22d ago
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
GlobeNewswire · 23d ago
Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target
MT Newswires · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.